Atlantic Bio Sci LLC, a Moorestown-based biotechnology company startup, is developing new oral drugs for the treatment of autoimmune diseases.
According to a press release, the company has started a 'Help Control Autoimmune Disease Now" crowdfunding project through MedStartr. The project will fund further development of the potential drug (ABS11) in preclinical studies of autoimmune diseases chosen from Type 1 diabetes, psoriasis, rheumatoid arthritis/juvenile arthritis, multiple sclerosis, lupus and colitis.
Raising additional funds more than the $10,000 goal moves Altantic Bio Sci closer to testing ABS11 in clinical trials in patients with autoimmune diseases. Contributions of any amount allow backers to vote for the autoimmune disease they choose to be tested in the next Atlantic Bio Sci study, the release said.
"Atlantic Bio Sci, LLC has a multifaceted approach to fundraising and we have chosen to start by taking the funding need directly to the public, including autoimmune disease patients and their loved ones, who will ultimately benefit from the work of Atlantic Bio Sci, LLC," the company said.
ALSO ON NJBIZ: